Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate
Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its...
Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as a preclinical candidate for its...